• 1
    Luqmani R, Hennell S, Estrach C, Birrell F, Bosworth A, Davenport G, et al, on behalf of the British Society for Rheumatology and British Health Professionals in Rheumatology, Guidelines and Audit Working Group. British Society for Rheumatology and British Health Professionals in Rheumatology guideline for the management of rheumatoid arthritis (the first two years). Rheumatology (Oxford) 2006; 45: 11679.
  • 2
    American College of Rheumatology Subcommittee on Rheumatoid Arthritis Guidelines. Guidelines for the management of rheumatoid arthritis: 2002 update. Arthritis Rheum 2002; 46: 32846.
  • 3
    Pincus T, Sokka T. Should aggressive therapy for rheumatoid arthritis require early use of weekly low-dose methotrexate, as the first disease-modifying anti-rheumatic drug in most patients? [editorial]. Rheumatology (Oxford) 2006; 45: 4979.
  • 4
    Pincus T, Yazici Y, Sokka T, Aletaha D, Smolen J. Methotrexate as the “anchor drug” for the treatment of rheumatoid arthritis. Clin Exp Rheumatol 2003; 21(5 Suppl 31 ): 17985.
  • 5
    Plant M, Jones P, Saklatvala J, Ollier W, Dawes P. Patterns of radiological progression in early rheumatoid arthritis: results of an 8 year prospective study. J Rheumatol 1998; 25: 41726.
  • 6
    Van der Heijde D. Joint erosions and patients with early rheumatoid arthritis. Br J Rheumatol 1995; 34 Suppl 2: 748.
  • 7
    Wolfe F, Sharp JT. Radiographic outcome of recent-onset rheumatoid arthritis: a 19-year study of radiographic progression. Arthritis Rheum 1998; 41: 157182.
  • 8
    Graudal N, Tarp U, Jurik A, Galloe A, Garred P, Milman N, et al. Inflammatory patterns in rheumatoid arthritis estimated by the number of swollen and tender joints, the erythrocyte sedimentation rate and hemoglobin: long-term course and association to radiographic progression. J Rheumatol 2000; 27: 4757.
  • 9
    Wolfe F, Zwillich SH. The long-term outcomes of rheumatoid arthritis: a 23-year prospective, longitudinal study of total joint replacement and its predictors in 1,600 patients with rheumatoid arthritis. Arthritis Rheum 1998; 41: 107282.
  • 10
    Grigor C, Capell H, Stirling A, McMahon A, Lock P, Vallance R, et al. Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single blind randomised controlled trial. Lancet 2004; 364: 2639.
  • 11
    Sharp JT, Strand V, Leung H, Hurley F, Loew-Friedrich I, on behalf of the Leflunomide Rheumatoid Arthritis Investigators Group. Treatment with leflunomide slows radiographic progression of rheumatoid arthritis: results from three randomized controlled trials of leflunomide in patients with active rheumatoid arthritis. Arthritis Rheum 2000; 43: 495505.
  • 12
    Pettit AR, Weedon H, Ahern M, Zehntner S, Frazer IH, Slavotinek J, et al. Association of clinical, radiological and synovial immunopathological responses to anti-rheumatic treatment in rheumatoid arthritis. Rheumatology (Oxford) 2001; 40: 124355.
  • 13
    Tishler M, Caspi D, Graff E, Segal R, Peretz H, Yaron M. Synovial and serum levels of methotrexate during methotrexate therapy of rheumatoid arthritis. Br J Rheumatol 1989; 28: 4223.
  • 14
    Kremer JM. Toward a better understanding of methotrexate [review]. Arthritis Rheum 2004; 50: 137082.
  • 15
    Cutolo M, Sulli A, Pizzorni C, Seriolo B, Straub R. Anti-inflammatory mechanisms of methotrexate in rheumatoid arthritis. Ann Rheum Dis 2001; 60: 72935.
  • 16
    Furst D, Koehnke R, Burmeister L, Kohler J, Cargill I. Increasing methotrexate effect with increasing dose in the treatment of resistant rheumatoid arthritis. J Rheumatol 1989; 16: 31320.
  • 17
    Seidman P. Preliminary report: methotrexate: the relationship between dose and clinical effect. Br J Rheumatol 1993; 32: 7513.
  • 18
    Dervieux T, Furst D, Lein DO, Capps R, Smith K, Walsh M, et al. Polyglutamation of methotrexate with common polymorphisms in reduced folate carrier, aminoimidazole carboxamide ribonucleotide transformylase, and thymidylate synthase are associated with methotrexate effects in rheumatoid arthritis. Arthritis Rheum 2004; 50: 276674.
  • 19
    Lafforgue P, Monjanel-Mouterde S, Durand A, Catalin J, Acquaviva P. Lack of correlation between pharmacokinetics and efficacy of low dose methotrexate in patients with rheumatoid arthritis. J Rheumatol 1995; 22: 8449.
  • 20
    Angelis-Stoforidis P, Vajda F, Christophidis N. Methotrexate polyglutamate levels in circulating erythrocytes and polymorphs correlate with clinical efficacy in rheumatoid arthritis. Clin Exp Rheumatol 1999; 17: 31320.
  • 21
    Dervieux T, Furst D, Lein DO, Capps R, Smith K, Caldwell J, et al. Pharmacogenetic and metabolite measurements are associated with clinical status in rheumatoid arthritis patients treated with methotrexate: results of a multicentred cross sectional observational study. Ann Rheum Dis 2005; 64: 11805.
  • 22
    Kremer J, Lein DO, Meyer G, Barham R, Simpson L, Do J, et al. Measurement of erythrocyte methotrexate polyglutamates predicts response to methotrexate therapy in a dose escalation study with rheumatoid arthritis patients [abstract]. Arthritis Rheum 2004; 50 Suppl 9: S1812.
  • 23
    Schroder H, Fogh K. Methotrexate and its polyglutamate derivatives in erythrocytes during and after weekly low-dose oral methotrexate therapy of children with acute lymphoblastic leukaemia. Cancer Chemother Pharmacol 1988; 21: 1459.
  • 24
    Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31: 31524.
  • 25
    Levy AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D, for the Modification of Diet in Renal Disease Study Group. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Ann Intern Med 1999; 130: 46170.
  • 26
    Dervieux T, Lein D, Marcelletti J, Pischel K, Smith K, Walsh M, et al. HPLC determination of erythrocyte methotrexate polyglutamates after low-dose methotrexate therapy in patients with rheumatoid arthritis. Clin Chem 2003; 49: 163241.
  • 27
    Brooks A, Begg E, Zhang M, Frampton C, Barclay M. Red blood cell methotrexate polyglutamate concentrations in inflammatory bowel disease. Ther Drug Monit 2007; 29: 61925.
  • 28
    Kremer JM, Lee JK. The safety and efficacy of the use of methotrexate in long-term therapy for rheumatoid arthritis. Arthritis Rheum 1986; 29: 82231.
  • 29
    Weinblatt ME, Trentham DE, Fraser PA, Holdsworth DE, Falchuk KR, Weissman BN, et al. Long-term prospective trial of low-dose methotrexate in rheumatoid arthritis. Arthritis Rheum 1988; 31: 16775.
  • 30
    Hoekstra M, Haagsma C, Neeg C, Proost J, Knuif A, van de Laar M. Splitting high dose oral methotrexate improves bioavailability: a pharmacokinetic study in patients with rheumatoid arthritis. J Rheumatol 2006; 33: 4815.
  • 31
    Braun J, Kastner P, Flaxenberg P, Wahrisch J, Hanke P, Demary W, et al, for the MC-MTX. 6/RH Study Group. Comparison of the clinical efficacy and safety of subcutaneous versus oral administration of methotrexate in patients with active rheumatoid arthritis: results of a six-month, multicenter, randomized, double-blind, controlled, phase IV trial. Arthritis Rheum 2008; 58: 7381.
  • 32
    Schroder H, Fogh K, Herlin T. In vivo decline of methotrexate and methotrexate polyglutamates in age-fractionated erythrocytes. Cancer Chemother Pharmacol 1988; 21: 1505.
  • 33
    Schroder H. Methotrexate pharmacokinetics in age-fractionated erythrocytes. Cancer Chemother Pharmacol 1986; 18: 2037.
  • 34
    Schalhorn A, Sauer H, Wilmanns W, Stupp-Poutot G. Pharmacokinetics of erythrocyte methotrexate after high-dose methotrexate. Cancer Chemother Pharmacol 1982; 9: 659.
  • 35
    Schroder H, Clausen N, Ostergaard E, Pressler T. Pharmacokinetics of erythrocyte methotrexate in children with acute lymphoblastic leukaemia during maintenance treatment. Cancer Chemother Pharmacol 1986; 16: 1903.
  • 36
    Kremer J, Rynes R, Bartholomew L. Severe flare of rheumatoid arthritis after discontinuation of long-term methotrexate therapy. Am J Med 1987; 82: 7816.